ArticlePediatric research2025
Increased AGEs/sRAGE ratio and dyslipidemia risk in Down syndrome youths: a cross-sectional study.
Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDown syndrome (DS) is associated with a higher risk of diseases linked to advanced glycation end products (AGEs) accumulation.
objectiveTo evaluate serum AGEs and their soluble receptor (sRAGE) levels in children and adolescents with DS and explore associations with anthropometric and biochemical variables.
methodsA cross-sectional study compared 51 DS participants (ages 3-18) with an age-matched control group (n = 51). Anthropometric measurements, blood chemistry, and lipid profiles were assessed. AGEs and sRAGE concentrations were determined by fluorescence and ELISA, respectively.
resultsDS individuals showed an unfavorable lipid profile, with higher triglycerides and lower HDL-C than controls. AGEs concentrations were significantly elevated in DS compared to controls (2.01 ± 0.48 vs. 1.33 ± 0.26 FAU/µg/mL; p < 0.001), while sRAGE levels were reduced (761.3 ± 433.7 vs. 1,196 ± 411.5 pg/mL; p < 0.001). The AGEs/sRAGE ratio was three times higher in the DS group than in controls (3.5 ± 1.9 vs. 1.2 ± 0.4; p < 0.001). Regression analysis identified HbA1c as a strong predictor of increased AGEs in both groups.
conclusionIndividuals with DS have an increased risk of dyslipidemia. Additionally, the elevated AGEs/sRAGE ratio associated with this genetic condition may reduce the protective effect of sRAGE against inflammatory processes. IMPACT STATEMENT: This is the first study to evaluate the AGEs/sRAGE ratio alongside biochemical and anthropometric markers in individuals with Down syndrome. DS individuals are at higher risk for dyslipidemia (elevated triglycerides, low HDL-C) and obesity, potentially linked to altered AGEs and sRAGE dynamics. Lower levels of sRAGE in DS may weaken its protective effects against tissue damage and inflammation caused by AGEs accumulation. HbA1c emerged as a strong predictor of AGEs, sRAGE, and the AGEs/sRAGE ratio in the DS cohort, highlighting the importance of monitoring glycemic control.
Indexed as
Identifiers
39930250What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.